Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have been given a consensus rating of “Strong Buy” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, one has given a buy recommendation and five have issued a strong buy recommendation on the company.
A number of research firms have commented on GLX. ATB Cormark Capital Markets downgraded shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Citizens Jmp upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th.
Check Out Our Latest Stock Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- The Next Commodity Crunch (bigger than oil?)
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Read this or regret it forever
- Unlocked: Elon Musk’s Next Big IPO
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
